We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed the most recent trading day at $42.73, moving -0.26% from the previous trading session. This move lagged the S&P 500's daily gain of 0.35%. Meanwhile, the Dow gained 0.03%, and the Nasdaq, a tech-heavy index, added 0.7%.
Heading into today, shares of the drugmaker had gained 2.66% over the past month, outpacing the Medical sector's gain of 1.51% and lagging the S&P 500's gain of 5.14% in that time.
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. This is expected to be April 30, 2019. In that report, analysts expect PFE to post earnings of $0.78 per share. This would mark year-over-year growth of 1.3%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.86 billion, down 0.32% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.86 per share and revenue of $52.90 billion. These results would represent year-over-year changes of -4.67% and -1.38%, respectively.
It is also important to note the recent changes to analyst estimates for PFE. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.06% lower. PFE is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that PFE has a Forward P/E ratio of 14.97 right now. Its industry sports an average Forward P/E of 15.3, so we one might conclude that PFE is trading at a discount comparatively.
Investors should also note that PFE has a PEG ratio of 2.58 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.08 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 29, which puts it in the top 12% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Pfizer (PFE - Free Report) closed the most recent trading day at $42.73, moving -0.26% from the previous trading session. This move lagged the S&P 500's daily gain of 0.35%. Meanwhile, the Dow gained 0.03%, and the Nasdaq, a tech-heavy index, added 0.7%.
Heading into today, shares of the drugmaker had gained 2.66% over the past month, outpacing the Medical sector's gain of 1.51% and lagging the S&P 500's gain of 5.14% in that time.
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. This is expected to be April 30, 2019. In that report, analysts expect PFE to post earnings of $0.78 per share. This would mark year-over-year growth of 1.3%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.86 billion, down 0.32% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.86 per share and revenue of $52.90 billion. These results would represent year-over-year changes of -4.67% and -1.38%, respectively.
It is also important to note the recent changes to analyst estimates for PFE. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.06% lower. PFE is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that PFE has a Forward P/E ratio of 14.97 right now. Its industry sports an average Forward P/E of 15.3, so we one might conclude that PFE is trading at a discount comparatively.
Investors should also note that PFE has a PEG ratio of 2.58 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.08 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 29, which puts it in the top 12% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.